AstraZeneca has recently launched a new global health tech business, Evinova, with the goal of revolutionizing clinical trials. The company aims to reduce the time and cost of clinical trials while making the process easier for patients. Evinova was created to fill a gap in the market for these services and will operate as a separate business from AstraZeneca.
Evinova will provide global services to CROs and pharmaceutical companies to design, run, and monitor clinical trials. The company will charge customers for access to its technology and will operate on a revenue-based model. This new business venture is expected to address the challenges and inefficiencies in the clinical trial process, ultimately making it easier for patients to participate and improving the overall effectiveness of the trials.
AstraZeneca’s commitment to advancing healthcare is reflected in this new business venture. By utilizing technology to improve the drug development process, AstraZeneca hopes to make clinical trials more efficient and accessible for everyone involved. Evinova’s success is likely to have a positive impact on patient outcomes, as well as on the bottom line for pharmaceutical companies and CROs.